A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)

Merck Sharp & Dohme LLC47 enrolled

Overview

This study aims to obtain plasma pharmacokinetic (PK) data and characterize the PK profile of imipenem (IMI), cilastatin (CIL), and relebactam (REL) following administration of a single intravenous (IV) dose of MK-7655A (a fixed ratio combination of imipenem/cilastatin/relebactam), hereafter referred to as IMI/REL.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Suspected or Documented Gram-negative Bacterial Infection

Interventions

IMI/REL FDCDRUG

IMI/REL is supplied as a single fixed dose combination (FDC) vial; which is administered at a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).

Eligibility

Sex: ALLMin age: 1 DayMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Has a parent or legally acceptable representative (LAR) who provides written informed consent for the trial on the participant's behalf. * Aged from birth to \<18 years old. * Is hospitalized, currently receiving antibacterial treatment for confirmed or suspected Gram-negative bacterial infection, and expected to require hospitalization until at least 24 hours after completion of study drug administration. * Is not of reproductive potential; but if of reproductive potential, agrees to avoid becoming pregnant or impregnating a partner from the time of consent through 24 hours after completion of study drug administration. * Has clinically stable renal function at the time of screening that is judged to be within acceptable ranges. * Has sufficient intravascular access to receive study drug through an existing peripheral or central line. Exclusion Criteria: * Has a personal history of hypersensitivity to imipenem/cilastatin (IMI) or to any of the following: any carbapenem, cephalosporin, penicillin, or other β-lactam agent; or other β-lactamase inhibitors (BLIs) e.g. tazobactam, sulbactam, clavulanic acid, avibactam. * Female is currently pregnant or breast feeding or has a positive serum β-human chorionic gonadotropin (β-hCG) pregnancy test. * Has a history of a seizure disorder requiring ongoing treatment with anti-convulsive therapy or prior treatment with anti-convulsive therapy within the last 3 years. * Has used or plans to use valproic acid or divalproex sodium within 2 weeks prior to screening or at any point between screening and 24 hours after the completion of study drug infusion. * Has received treatment or plans to receive treatment with any carbapenem antibiotic within 48 hours prior to initiation of study drug infusion or at any point between administration of study drug and the last PK sample collection. * Has used or plans to use any of the following medications, which are organic anion transporter (OAT) 1 or OAT3 inhibitors, within 1 week prior to screening or at any point between screening and the last PK sample collection: cimetidine, probenecid, indomethacin, mefenamic acid, furosemide or other loop diuretics (eg, bumetanide, torsemide, ethacrynic acid), angiotensin receptor blockers (eg, valsartan), and ketorolac. * Is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 30 days prior to screening. * Has enrolled previously in the current trial and been discontinued, or has received REL for any other reason. * Has a current diagnosis of cystic fibrosis, meningitis, or severe sepsis. * Is expected to survive less than 72 hours after completion of study drug administration. * Has a history of clinically significant renal, hepatic, or hemodynamic instability. * Plans to use cardiopulmonary bypass, extracorporeal membrane oxygenation, hemodialysis, or peritoneal dialysis during the study. * For participants that are 2 to 17 years of age only: weighs outside of the 5th to 95th percentile based on age. * Is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence. * Has a planned blood transfusion within 24 hours of study drug administration or expected before the end of the PK sampling. * Has had significant blood loss (≥5% of total blood volume) within 4 weeks before the screening visit.

Locations (33)

Outcomes

Primary Outcomes

Imipenem (IMI) Area Under the Concentration Time Curve From Time 0 to Infinity (AUC0-∞)

Area under the concentration time curve from time 0 to infinity (AUC0-∞) of plasma imipenem (IMI) was calculated. AUC0-∞ is the area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time.

Time frame: 30 minutes (min) before start of drug infusion (DI) and 10 min after the end of DI for all cohorts; 1.5 to 2.5 hours (hrs) and 4.5 to 6 hrs after start of DI for Cohorts 1-4; 2 to 5 hrs and 6 to 12 hrs after start of DI for Cohort 5

IMI Maximum Concentration (Cmax)

Maximum plasma concentration (Cmax) of IMI was calculated. Cmax is the peak plasma concentration of study drug after administration.

IMI Central Volume of Distribution (Vc)

Central volume of distribution (Vc) of plasma IMI was calculated.

IMI Clearance (CL)

Systemic clearance (CL) of plasma IMI was calculated.

IMI Percentage of Time Above the Minimum Concentration (%TMIC)

Percentage of time spent above the minimum inhibitory concentration (%TMIC) of plasma IMI was calculated. %TMIC is defined as the percentage of time (in hours) in which the lowest concentration of a study drug, completely inhibits growth of the specific organism being tested.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Arkansas Children's Hospital ( Site 1311)

Little Rock, Arkansas, United States

Children's Hospital of Orange County ( Site 1301)

Orange, California, United States

Rady Children's Hospital-San Diego ( Site 1305)

San Diego, California, United States

Our Lady of the Lake Hospital ( Site 1304)

Baton Rouge, Louisiana, United States

St. Louis Children's Hospital ( Site 1322)

St Louis, Missouri, United States

Duke University Medical Center ( Site 1317)

Durham, North Carolina, United States

The Children's Hospital of Philadelphia ( Site 1318)

Philadelphia, Pennsylvania, United States

Seattle Childrens Hospital ( Site 1321)

Seattle, Washington, United States

MHAT Pazardjik AD ( Site 0208)

Pazardzhik, Pazardzhik, Bulgaria

UMHAT Deva Maria. EOOD ( Site 0209)

Burgas, Bulgaria

...and 23 more locations

Relebactam (REL) AUC0-∞

Area under the concentration time curve from time 0 to infinity (AUC0-∞) of plasma relebactam (REL) was calculated. AUC0-∞ is the area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time.

REL Maximum Concentration (Cmax)

Maximum plasma concentration (Cmax) of REL was calculated. Cmax is the peak plasma concentration of study drug after administration.

REL Clearance (CL)

Systemic clearance (CL) of plasma REL was calculated.

REL Central Volume of Distribution (Vc)

Central volume of distribution (Vc) of plasma REL was calculated.

Cilastatin (CIL) AUC0-∞

Area under the concentration time curve from time 0 to infinity (AUC0-∞) of plasma cilastatin (CIL) was not calculated. AUC0-∞ is the area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time.

CIL Time to Maximum Concentration (Tmax)

Time to maximum plasma concentration (Tmax) of CIL was determined. Tmax is defined as the time after drug administration at which peak drug concentration in plasma occurs.

CIL Concentration at End of Infusion (Ceoi)

Concentration at end of infusion (Ceoi) of plasma CIL was determined.

Time frame: 30 min after the start of infusion for Cohort 1; 60 min after the start of infusion for Cohorts 2-5

CIL Terminal Half-Life (t1/2)

Terminal half-life (t1/2) of plasma CIL was not calculated.

CIL Clearance (CL)

Systemic clearance (CL) of plasma CIL was not calculated.

CIL Volume of Distribution (Vss)

Volume of distribution (Vss) of plasma CIL was not calculated.

Secondary Outcomes

Number of Participants Who Experienced an Adverse Event (AE)

Number of participants with one or more AEs was calculated. An AE is defined as any untoward medical occurrence in a participant administered study drug and which may or may not have a causal relationship to the study drug.

Time frame: Up to 17 days

Number of Participants Who Discontinued Study Drug Due to an AE

Number of participants who discontinued study drug due to an AE was calculated. An AE is defined as any untoward medical occurrence in a participant administered study drug and which may or may not have a causal relationship to the study drug.

Time frame: Day 1